文献速递白血病

基因组PCR分析深度分子学反应期慢性髓性白血病:一种影响无治疗缓解的红绿灯分层模型

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
PubMed 文献 · Leukemia · 2020-05-29

该研究探讨基因组BCR-ABL1融合作为慢性髓性白血病可测量残留病标志物,比较DNA与mRNA qPCR及数字PCR检测,提出基于DMR维持期DNA/RNA BCR-ABL1结果的红绿灯分层模型预测TKI停药后无分子复发生存。

要点

  • DMR期DNA与RNA BCR-ABL1相关性差,MR4以上相关性高。
  • DNA阴性/RNA阴性组18个月MRFS为80%(停药)和100%(中断)。
  • DNA阳性/RNA阳性组MRFS均为20%,红绿灯分层或可预测TFR。

核心结论

  • 基于DMR维持期DNA和mRNA BCR-ABL1测量的红绿灯分层可作为TKI停药后TFR的预测指标。

研究设计与样本

  • 比较DNA与mRNA BCR-ABL1 qPCR在2189份样本(129例患者)中的检测,数字PCR在1279份样本(62例患者)中检测。
  • 分析TKI停药(n=17)或计划中断(n=25)后分子复发无生存(MRFS)。

主要发现

  • 疾病水平高于MR4时DNA与RNA BCR-ABL1高度相关,DMR期间相关性差。
  • 停药后18个月,DNA阴性/RNA阴性组(绿组)MRFS为80%(停药)和100%(中断)。
  • DNA阳性/RNA阴性组(黄组)MRFS为57%(停药)和67%(中断)。
  • DNA阳性/RNA阳性组(红组)两队列MRFS均为20%。

关键数值与推荐

  • 绿组:DNA阴性/RNA阴性,18个月MRFS 80%(停药)和100%(中断)。
  • 黄组:DNA阳性/RNA阴性,18个月MRFS 57%(停药)和67%(中断)。
  • 红组:DNA阳性/RNA阳性,18个月MRFS均为20%。

临床怎么用

  • 原文提出红绿灯分层作为TKI停药前DMR维持期基于DNA和mRNA BCR-ABL1测量的TFR预测指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n = 17) or scheduled interruption (n = 25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS = 57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS = 20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Machova Polakova K, Zizkova H, Zuna J, et al. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia. 2020. PMID: 32472084. doi:10.1038/s41375-020-0882-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。